GlassScriptPhysician profile
Johnny Jimenez
NPI 1659831725
$5,238.75
in general payments reported to CMS, 2019-2025
29 companies · $1,875 in 2025
The $1,875 reported for 2025 was more than what 95% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $327 · 2023: $1,443 · 2024: $1,594 · 2025: $1,875.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,912.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,912.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $603.19 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $501.06 | 2024-2025 | Voquezna |
| Incyte Corporation | $369.69 | 2023-2024 | Opzelura |
| Teva Pharmaceuticals USA, INC. | $250.00 | 2022-2023 | Uzedy |
| Novo Nordisk INC | $249.99 | 2022-2025 | Wegovy |
| Sanofi-Aventis U.S. LLC | $246.84 | 2024-2025 | |
| Abbott Laboratories | $215.56 | 2023-2024 | Freestyle Libre 3 |
| Corcept Therapeutics | $199.70 | 2023-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $161.23 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $146.20 | 2024 | Iqirvo |
| Biosense Webster, INC. | $141.36 | 2025 | Nuvision Ice Catheter |
| Alnylam Pharmaceuticals INC. | $133.44 | 2025 | Onpattro |
| Amgen INC. | $125.00 | 2023 | Repatha |
| Ardelyx, INC. | $125.00 | 2025 | Ibsrela |
| Lilly USA, LLC | $125.00 | 2024 | Mounjaro |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $125.00 | 2023 | |
| Eisai INC. | $125.00 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2024 | |
| Argenx US, INC. | $124.99 | 2024 | Vyvgart |
| Idorsia Pharmaceuticals US INC | $124.82 | 2023 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $122.77 | 2025 | Xifaxan |
| Ironwood Pharmaceuticals, INC | $122.70 | 2024 | |
| Qol Medical, LLC | $122.05 | 2025 | Sucraid |
| Ultragenyx Pharmaceutical INC. | $121.87 | 2023 | Crysvita |
| Mayne Pharma Commercial LLC | $121.83 | 2024 | |
| Abiomed | $118.64 | 2025 | |
| Acadia Pharmaceuticals INC | $113.47 | 2025 | Nuplazid |
| Axsome Therapeutics, INC. | $100.69 | 2025 | Auvelity |
| Scynexis, INC. | $76.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Johnny Jimenez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.